We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Rebecca
Fitzgerald
rcf29@mrc-cu.cam.ac.uk
Tara
Evans
tn278@cam.ac.uk
Mrs
Nicola
Grehan
nicola.grehan@addenbrookes.nhs.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Oesophageal cancer is the 8th most common cancer and the 6th most frequent cause of mortality for cancer worldwide. Despite improvements in cancer therapy, oesophageal cancer remains a very aggressive disease with a 5-year survival rate of 19% in Western Countries, and less than 10% in developing countries. There are two main types of oesophageal cancer: oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma.
Worldwide OSCC is the predominant sub-type, with a particularly high incidence in Asia. In the UK OSCC account for around 40% of oesophageal cancer cases. Squamous cell dysplasia is a precancerous condition to OSCC. While the risk factors and the genetic changes driving the development of OSCC are well understood in different geographies, the molecular alterations leading to squamous cell dysplasia and its progression to invasive cancer are less understood and have been so far been vastly understudied. Understanding the molecular events is the first step towards developing novel tests for diagnosis and individualized treatment.
In the current study, we hypothesise that molecular alterations that characterise the development of OSCC can be used to develop clinically relevant diagnostic biomarkers to improve early diagnosis, tumour classification and therapeutic management.
The aims of the study are to:
• Identify key molecular changes that occur as squamous dysplasia develops and progresses into invasive OSCC
• Develop clinical assays for early detection of disease
• Develop and validate improved staging and prognostic algorithms based on molecular biomarkers to inform therapeutic decisions
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Device;Cellular;Management of Care;Surgery;Active Monitoring;
You can take part if:
You may not be able to take part if:
The exclusion criteria will depend on the procedure to be undergone. Blood samples and Endoscopic biopsies: - On anticoagulation therapy /medication (warfarin, clopridogrel, heparin or tinzaparin) on the day of their procedure Cytosponge samples (not Cancer group): - Individuals with a diagnosis of oropharyngeal cancer, an established, invasive oesophageal or gastro-oesophageal tumour (T2 or more) or symptoms of dysphagia - Oesophageal varices, stricture or requiring dilatation of the oesophagus - On anticoagulation therapy/medication (warfarin, clopridogrel, heparin or tinzaparin) on the day of their procedure - Individuals who have had a myocardial infarction or any cardiac event less than six months ago - Individuals who have had a cerebrovascular event < 6 months ago where their swallowing has been affectedProbe-based confocal laser endomicroscopy (not Cancer group) - Severe asthma - Allergy to fluorescein
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Rebecca
Fitzgerald
rcf29@mrc-cu.cam.ac.uk
Tara
Evans
tn278@cam.ac.uk
Mrs
Nicola
Grehan
nicola.grehan@addenbrookes.nhs.uk
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 20214
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
